Christopher Dean - Concepedia

Author

Christopher Dean

Also Known As

C DEAN, C Dean, C J Dean, C. Dean, C. J. Dean, C.J. DEAN, C.J. Dean, CHRISTOPHER J. DEAN, Christopher Dean, Christopher J Dean

112

Publications

Citations

H-Index

103

Concepts

All Affiliations

Institute of Cancer Research Barts Health NHS Trust Royal Marsden NHS Foundation Trust Middlesex University Royal Marsden Hospital

About

Christopher Dean is an author at Institute of Cancer Research specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	1K
2	Health Sciences	4	4	89
3	Engineering	3	3	74
4	Allergy	3	3	80
5	Natural Sciences	1	1	25

Christopher Dean

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
THE RECEPTOR FOR EGF AND ITS LIGANDS - EXPRESSION, PROGNOSTIC VALUE AND TARGET FOR THERAPY IN CANCER (REVIEW) Helmout Modjtahedi, Christopher Dean International Journal of Oncology Growth Factor ReceptorsSignaling PathwayMedicineReceptor Tyrosine KinasePathology	1994	138
Brk, a Breast Tumor-derived Non-receptor Protein-tyrosine Kinase, Sensitizes Mammary Epithelial Cells to Epidermal Growth Factor Tahereh Kamalati, Helen E. Jolin, Philip J. Mitchell, Journal of Biological Chemistry	1996	124
Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer Helmout Modjtahedi, Tamas Hickish, Margery Nicolson, British Journal of Cancer Malignant DiseaseMedicineImmunologyPathologyBronchial Neoplasm	1996	102
Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Sue Eccles, William Court, Gary Box, PubMed Mda Mb 361Breast OncologyPathologyCancer BiologyTumor Biology	1994	80
An evaluation of four CT–MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patients Christopher Dean, Jonathan Sykes, Rachel Cooper, British Journal of Radiology	2011	72
Ricin B chain converts a non‐cytotoxic antibody‐ricin A chain conjugate into a potent and specific cytotoxic agent Deirdre P. McIntosh, D. C. Edwards, A.J. Cumber, FEBS Letters	1983	68
Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction Helmout Modjtahedi, S. A. Eccles, G. Box, British Journal of Cancer Tumor BiologyHuman Tumour XenograftsMedicineImmunologyRat Antibodies	1993	65
Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Helmout Modjtahedi, S. A. Eccles, J Sandle, PubMed Terminal DifferentiationRat Monoclonal AntibodiesMedicineImmunologyTumor Immunity	1994	60
Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy Helmout Modjtahedi, David K. Moscatello, Gary Box, International Journal of Cancer	2003	60
Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Pamela Dunn, Christine A. Johnson, J M Styles, PubMed Immunocytochemical TechniqueImmunologyImmunodominancePathologyImmunotherapeutics	1987	57

Page 1